Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKB | Q96GD4 | 15/20 | 0.44 |
| ▸ | AURKA | O14965 | 14/20 | 0.44 |
| ▸ | LCK | P06239 | 2/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.44 |
| ▸ | CDK2 | P24941 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.44 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.44 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.44 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13899549 | 0.88 | AURKB (0.46) | AURKBAURKALCKCHEK1EGFR | |
| SCHEMBL13899630 | 0.86 | AURKB (0.51) | AURKBAURKALCKCHEK1EGFR | |
| SCHEMBL13899514 | 0.86 | AURKB (0.44) | AURKBAURKALCKCHEK1EGFR | |
| SCHEMBL13899525 | 0.82 | PTK6 (0.47) | AURKBAURKALCKCHEK1EGFR | |
| SCHEMBL14538362 | 0.82 | LCK (0.46) | AURKBAURKALCKCHEK1EGFR | |
| SCHEMBL13899629 | 0.81 | PTK6 (0.44) | AURKBAURKALCKCHEK1EGFR | |
| SCHEMBL13899609 | 0.81 | AURKA (0.49) | AURKBAURKALCKCHEK1EGFR | |
| SCHEMBL14533851 | 0.80 | AURKB (0.47) | AURKBAURKALCKCHEK1EGFR | |
| SCHEMBL13155373 | 0.76 | LCK (0.75) | AURKBAURKALCKCHEK1EGFR | |
| SCHEMBL13899597 | 0.69 | AURKA (0.43) | AURKBAURKALCKCHEK1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7511040-B2 | Imidazopyrazines as protein kinase inhibitors | SCHERING CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-20080139571-A1 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139571-A1 | IMIDAZOPYRAZINES AS PROTEIN KINASE INHIBITORS | AURKC, AURKA, AURKB | AURKB 3/4885AURKA 2/4885LCK 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.